| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CVRx, Inc.$5.43
+0.23 (+4.42%)
D 29Pipeline Score MedTech · Commercial
Market Cap
162.13 M
EPS
-2.01
P/E Ratio
-
Value Trade
1.54 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
14.77 M
R&D Expenses
3.08 M
Operating CF
-12.16 M
Total Assets
99.73 M
Total Liabilities
70.62 M
Equity
29.11 M
D/E Ratio
12,345
7.19 %
Week
-20.13 %
1 Month
16.16 %
3 Month
-30.01 %
6 Month
-76.72 %
5 Year
-76.72 %
All Time
Cash Data
Cash Position
72.30 M
Monthly Burn
4.05 M
Runway
16.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
140.46 K
52 Week Range
4.37 - 11.30
% held by Insiders
43.53 %
% held by Institutions
28.87 %
Enterprise Value
149.23 M
Total Shares
26.41 M
Short %
13.87 %
Float Shares
13.26 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankCVRx, Inc. faces pipeline headwinds (29/100), with 1 assets in development.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Barostim | heart failure | — | 2026-03-02 | six-month outcomes in over 400 patients | CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting Read More | |
Barostim | heart failure | — | 2026-03-02 | six-month outcomes in over 400 patients | CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting Read More | |
Barostim | heart failure | — | 2026-03-02 | six-month outcomes in over 400 patients | CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CVRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CVRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CVRXCVRx Announces Chief Financial Officer Transition MINNEAPOLIS
CVRx announced that Jared Oasheim, their Chief Financial Officer, will be stepping down to pursue other opportunities. Mr. Oasheim will remain with the company until a successor is appointed and will act as an advisor through February 2027. He has been with CVRx since 2015, contributing significantly to its financial structure and successful IPO. The company is currently searching for a new CFO and continues to focus on its innovative neuromodulation solutions for cardiovascular patients.
Read more →CVRXCVRx Announces Chief Financial Officer Transition
CVRx, Inc. announced the transition of its Chief Financial Officer, Jared Oasheim, who will step down to pursue other opportunities. Oasheim will assist with the transition until a successor is appointed and will remain as an advisor until February 2027. His leadership has been pivotal in the company's growth, including its IPO and financial foundation.
Read more →CVRXCVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRx, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The presentation will highlight their innovative neuromodulation solutions for cardiovascular diseases, particularly the Barostim device, which is FDA-approved for heart failure. A live webcast will be available for interested parties.
Read more →CVRXCVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc. will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The presentation will highlight the company's innovative neuromodulation solutions for cardiovascular diseases, particularly focusing on their FDA-approved device, Barostim. A live webcast will be available, with an archived version accessible later.
Read more →CVRX▲ +10%on this news
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx has announced that Humana will provide Medicare Advantage coverage for Barostim therapy starting May 1, 2026. This policy is significant as it marks the first coverage for Barostim, aimed at improving access for heart failure patients. The announcement follows other positive reimbursement developments and reflects ongoing efforts to educate payers about the therapy's benefits.
Read more →CVRXCVRx Reports First Quarter 2026 Financial and Operating Results
CVRx, Inc. reported a strong financial performance for Q1 2026, with total revenue reaching $14.8 million, a 20% increase from the previous year. U.S. revenue also saw a notable rise of 22%, driven by growth in the heart failure business. The company activated its first site and enrolled its first patient in the BENEFIT-HF clinical trial, aiming to expand the Barostim indication significantly.
Read more →CVRXCVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx has announced the enrollment of the first patient in the BENEFIT-HF trial, which aims to evaluate the Barostim therapy in a significantly expanded heart failure population. The trial is expected to enroll 2,500 patients across 150 centers in the U.S. and Germany. If successful, it could potentially triple the patient population eligible for Barostim therapy, enhancing access for those suffering from heart failure.
Read more →CVRXCVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx, Inc. will announce its first quarter 2026 financial results on May 11, 2026. A conference call will follow at 4:30 p.m. ET to discuss these results. The company specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure treatment.
Read more →CVRXCVRx Announces Nomination of Michael Dale for Election to the Board of Directors
CVRx, Inc. has nominated Michael Dale for election to its Board of Directors at the upcoming annual meeting on June 1, 2026. Dale, who is currently the CEO of Axogen, Inc., has a strong background in the medical device sector, which CVRx believes will enhance its strategic direction, particularly in promoting its Barostim therapy for heart failure.
Read more →CVRX▲ +9.2%on this news
CVRx Reports Preliminary First Quarter 2026 Financial Results
CVRx reported preliminary financial results for Q1 2026, projecting revenues of $14.7 to $14.8 million, marking a 20% increase from the previous year. The company noted improved Medicare Advantage prior authorization rates and activated the first site for the BENEFIT-HF clinical trial. Despite increased operating expenses, the gross margin is expected to reach 87%.
Read more →CVRXCVRx, Inc. Investigated by the Portnoy Law Firm
CVRx, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, with a potential class action being considered for investors. The investigation follows a significant decline in CVRx's stock price, which plummeted 46.3% after the company reported disappointing first quarter revenues. Subsequent announcements regarding lower full-year revenue guidance and challenges in the integration of new sales personnel have further impacted investor confidence. This situation has led to a steep decline in share value, prompting legal scrutiny.
Read more →CVRXCVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx, Inc. announced the schedule for scientific presentations at the THT 2026 meeting, focusing on Barostim therapy outcomes. The presentations will include late-breaking data from the REBALANCE Registry, showcasing the therapy's safety and benefits in over 400 patients. The conference will feature various sessions on cardiac energetics and hospitalization impacts related to Barostim.
Read more →CVRX▼ -6.4%on this news· ran to -20% by day 3
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results MINNEAPOLIS
CVRx, Inc., a medical device company, reported its financial results for Q4 and full year 2025, showcasing a revenue increase to $56.7 million, up 10% year-over-year. The U.S. revenue also grew by 10%, aided by an increase in active implanting centers. CVRx announced the initiation of the BENEFIT-HF trial, expected to enhance market access. However, the company continues to face significant net losses, amounting to $53.3 million for the year.
Read more →CVRXCVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx, Inc. plans to announce its fourth quarter 2025 financial results on February 12, 2026, after market close. The company will host a conference call at 4:30 p.m. ET to discuss these results. CVRx specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being the first FDA-approved technology in this area.
Read more →CVRXCVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into CVRx Inc. on behalf of its stockholders, following significant declines in stock price related to disappointing financial results. The investigation is focused on potential violations of federal securities laws and unlawful business practices by the company. In April and May of 2025, CVRx announced weaker than expected earnings and lowered its revenue guidance, causing substantial share price drops.
Read more →CVRX▲ +11.4%on this news
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx has initiated the BENEFIT-HF clinical trial to evaluate the Barostim device in a larger heart failure population. This landmark study will involve 2,500 patients across 150 centers in the U.S. and Germany, aiming to assess its impact on mortality and heart failure events. The trial is backed by CMS coverage, facilitating patient access during the study.
Read more →CVRX▼ -9.9%on this news· ran to -33% by day 3
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
CVRx, Inc. reported strong preliminary financial results for the fourth quarter and full year 2025, highlighting a revenue growth of 10% to 11%. The company is optimistic about 2026, forecasting revenue between $63 million and $67 million, supported by new CPT codes facilitating reimbursement. Recent FDA approval for the BENEFIT-HF trial design further enhances confidence in their neuromodulation solutions for heart failure. However, the significant cost associated with the trial and the need for CMS coverage approval introduces some uncertainty.
Read more →CVRXCVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
CVRx, Inc. announced the approval of new Category I CPT codes for its Barostim therapy, which replaces the prior Category III codes effective Jan. 1, 2026. These codes are expected to enhance reimbursement predictability and validation for Barostim as a vital component in heart failure treatment. The Barostim device uses neuromodulation to alleviate heart failure symptoms and is FDA-approved. CVRx urges healthcare professionals to update their billing practices to incorporate these new codes.
Read more →CVRXCVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full ye
CVRx, Inc. has reported preliminary financial results indicating fourth quarter revenues of approximately $15.9 million to $16.1 million, which reflects a growth of 4-5% from the previous year. The company also issued guidance for 2026, noting its expectation to report revenues between $13.7 million and $14.7 million for the first quarter. The transition to Category I CPT codes marks a significant advance in the company’s commercial efforts. Additionally, advancements in their clinical trial for Barostim provide a positive outlook for future growth.
Read more →CVRXCVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
CVRx, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will showcase their innovative neuromodulation solutions for cardiovascular diseases, particularly focusing on their FDA-approved device, Barostim. A live webcast will be available, with an archived version accessible later.
Read more →CVRXCVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
CVRx, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 3, 2025. The management team will engage in a fireside chat that will be available via webcast. The company focuses on developing neuromodulation solutions for cardiovascular diseases, including its FDA-approved Barostim device, which addresses heart failure symptoms.
Read more →CVRXCVRx Reports Third Quarter 2025 Financial and Operating Results
CVRx, Inc. reported a 10% increase in revenue for Q3 2025, totaling $14.7 million. The company noted positive developments in its commercial strategy and expansion of sales territories. However, it also reported a net loss of $12.9 million, with increased expenses in R&D and SG&A. The transition to Category I CPT codes is expected to enhance patient access to their Barostim device.
Read more →CVRXCVRx to Present at the Jefferies Global Healthcare Conference in London
CVRx, Inc. will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The presentation will highlight their innovative neuromodulation solutions for cardiovascular diseases, particularly their FDA-approved device, Barostim. The event will be accessible via a live audio webcast on the company's investor relations page.
Read more →CVRXCVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
CVRx, Inc. announced its plans to release its third quarter 2025 financial and operating results after market close on November 5, 2025. The company will also host a conference call at 4:30 p.m. ET on the same day to review the results. CVRx specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being the first FDA-approved technology of its kind aimed at improving heart failure symptoms. The device has also received compliance certifications in Europe.
Read more →CVRXCVRx Reports Second Quarter 2025 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported its financial and operating results for the second quarter of 2025, showing a 15% increase in revenue to $13.6 million compared to the same period in 2024. The company is experiencing growth in its U.S. HF business, with an increase in active implanting centers and sales territories. Significant advancements in reimbursement strategies, including proposed CMS payment classifications, suggest a strengthening position in the market. However, CVRx also reported an increase in net loss and higher operating expenses, despite a notable transformation in its sales force and the appointment of a new COO.
Read more →CVRXCVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
CVRx, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The presentation is scheduled for 3:00 PM Eastern Time and will be available via webcast. The company specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure treatment.
Read more →CVRXCVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
CVRx, Inc. will announce its second quarter 2025 financial results on August 4, 2025, after market close. The company will also host a conference call at 4:30 PM ET to discuss these results. CVRx specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure treatment.
Read more →CVRX▲ +19%on this newsshared move
CVRx Announces Positive News on Outpatient Payment for Barostim
CVRx announced that CMS will maintain the Barostim implant procedure in APC 1580, allowing for a payment of approximately $45,000 for outpatient procedures. This follows recent positive reimbursement updates, including a transition to a higher paying MS-DRG for inpatient procedures and a change to Category I CPT codes. The company anticipates these changes will enhance access for heart failure patients.
Read more →CVRXCVRx to Present at the William Blair 45th Annual Growth Stock Conference
CVRx, Inc. will present at the William Blair 45th Annual Growth Stock Conference on June 4, 2025. The presentation will be available via webcast at 10:00am Central Time. The company specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure.
Read more →CVRXCVRx Reports First Quarter 2025 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. has reported its financial and operational results for the first quarter of 2025, revealing a total revenue of $12.3 million, a 15% increase from the previous year. The company's heart failure revenue reached $11.1 million, reflecting a 14% growth. Although the revenue growth did not meet expectations, the company has seen an increase in active implanting centers and reported significant reductions in hospital visits for Barostim patients. They anticipate total revenue for 2025 to be between $55.0 million and $58.0 million.
Read more →CVRX▲ +6.1%on this news· ran to +21% by day 3
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
CVRx, Inc. (NASDAQ: CVRX) has announced that it will report its first quarter 2025 financial and operating results after the market closes on May 8, 2025. Following the announcement, the company will host a conference call to discuss these results at 4:30 PM Eastern Time. CVRx specializes in developing neuromodulation solutions for cardiovascular diseases, with its Barostim device being the first FDA-approved technology of its kind for heart failure patients.
Read more →CVRXCVRx Reports Preliminary First Quarter 2025 Financial Results First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 MINNEAPOLIS
CVRx reported preliminary financial results for the first quarter of 2025, expecting a revenue of approximately $12.3 million, which is a 15% increase compared to the same quarter in 2024. However, the results fell short of expectations, attributed to a decrease in sales territories and seasonal softness impacting patient procedures. The company is focused on strengthening its sales organization and is optimistic about the adoption of its Barostim device. Full financial results will be announced in May, along with a comprehensive outlook for the fiscal year 2025.
Read more →CVRXCVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
CVRx, Inc. announced the presentation of new real-world evidence at the THT conference, showing significant reductions in healthcare utilization post-Barostim implantation. The study found an 86% reduction in all-cause hospital visits, alongside substantial decreases in both cardiovascular and heart failure-related hospitalizations. Conducted using data from over 1,300 institutions, this analysis reinforces the clinical utility of Barostim, which employs neuromodulation to treat heart failure and is FDA-approved. The findings are essential for guiding clinical and payer decisions regarding heart failure treatment with this device.
Read more →CVRX▲ +5.1%on this news
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported robust financial results for the fourth quarter and full year of 2024, highlighting a 41% increase in U.S. heart failure revenue. The company's President and CEO noted the achievement of critical reimbursement milestones and an increase in active implanting centers. However, despite these gains, the company also reported a net loss of $10.7 million for Q4 and $60 million for the full year, raising concerns over financial sustainability amidst rising expenses and market challenges in Europe.
Read more →CVRXCVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
CVRx, Inc. announced it will release its fourth quarter 2024 financial and operating results on February 4, 2025, after market close. The company will host a conference call that same day at 4:30 PM ET to review these results. CVRx is known for its Barostim device, which uses neuromodulation to address heart failure and has received FDA approval as well as CE Mark certification. The company aims to enhance treatments for patients with cardiovascular diseases.
Read more →CVRX▲ +6.1%on this news· ran to +22% by day 3
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% Full year re
CVRx, Inc. has reported preliminary financial results for the fourth quarter and full year 2024, highlighting a strong performance with total revenue expected between $15.2 million and $15.3 million, a 35% increase from Q4 2023. The company anticipates a full year revenue increase to approximately $51.1 million to $51.2 million, reflecting a 30% growth compared to the previous year. Additionally, CVRx provided guidance for 2025, projecting further revenue growth and emphasizing the successful execution of its commercial strategy, which includes expanding clinical evidence and improving patient access. The company will be presenting at the upcoming J.P. Morgan Healthcare Conference.
Read more →CVRXCVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CVRx, Inc. (NASDAQ: CVRX) announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will cover their Barostim System, which is notable for being the first medical technology approved by the FDA using neuromodulation for heart failure treatment. Barostim has received favorable designations and approvals in both the U.S. and European markets. The live audio webcast of the presentation will be accessible on the company's investor relations webpage.
Read more →CVRXCVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx, Inc. announced it will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The presentation will focus on the Barostim System, which is the first FDA-approved device that utilizes neuromodulation for heart failure treatment. This innovative technology has received both FDA approval and CE Mark, emphasizing its significance in the healthcare sector. A live audio webcast of the presentation will be accessible on the company’s investor relations page.
Read more →CVRX▲ +12.3%on this news
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
CVRx, Inc. announced that the CMS has classified the Barostim procedure under a high outpatient payment category for 2025, solidifying the procedure's reimbursement structure. This update follows the AMA's approval for the transition of Barostim to Category I CPT codes, effective January 1, 2026. Additionally, an increase in payments for inpatient procedures reflects a recognition of the device's clinical value. These developments aim to improve access to the Barostim therapy, supporting its commercial growth.
Read more →CVRXCVRx Reports Third Quarter 2024 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported a 27% increase in revenue for Q3 2024, reaching $13.4 million, driven by greater adoption of its Barostim therapy. The company noted positive developments with improved inpatient reimbursement and long-term quality of life data, enhancing Barostim's market position. Despite these achievements, CVRx experienced a larger net loss of $13.1 million compared to the previous year. The company continues to expand its operational capacity, increasing the number of active implanting centers and sales territories.
Read more →CVRX▲ +17.2%on this news
CVRx announces new CPT Category I codes for Barostim
CVRx, Inc. announced that the AMA has accepted new CPT Category I codes for its Barostim therapy, aimed at treating heart failure symptoms. This decision is expected to facilitate better reimbursement and increase patient access to the treatment. The new codes are set to be implemented on January 1, 2026, while existing Category III codes will be used until then. CEO Kevin Hykes emphasized this milestone as a recognition of the therapy's safety and effectiveness. However, there are uncertainties regarding actual reimbursement levels pending further surveys by the AMA.
Read more →CVRXCVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
CVRx, Inc. will report its financial and operating results for the third quarter of 2024 after market closure on October 29, 2024. The company plans to host a conference call at 4:30 PM ET on the same day to discuss these results. CVRx is known for its Barostim™ device, which is designed to improve symptoms in heart failure patients and has received several regulatory approvals including FDA Breakthrough Device designation.
Read more →CVRX▼ -6.2%on this news
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
CVRx, Inc. has published new data demonstrating the long-term quality of life benefits of Barostim therapy for heart failure patients with reduced ejection fraction. The findings, published in JACC: Heart Failure, indicate durable improvements in quality of life measures after 24 months. Patients receiving Barostim alongside guideline-directed medical therapy reported better physical and psychosocial outcomes compared to those on medical therapy alone. This publication builds on the previously reported BeAT-HF trial data, highlighting the sustained symptomatic benefits of the therapy.
Read more →CVRX▼ -8.2%on this news
CVRx Announces Appointment of Two New Board Members
CVRx, a commercial-stage medical device company, has announced the addition of Kevin Ballinger and Mitch Hill to its Board of Directors, effective immediately. Their appointments come as long-serving member Ali Behbahani departs, leaving the board with seven members. Ballinger brings over 25 years of experience in the medical device industry, while Hill has over 30 years of financial and operational experience in healthcare. The company is focused on expanding the adoption of its Barostim therapy, a breakthrough device for heart failure treatment.
Read more →CVRX▲ +5.2%on this news
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is conducting an investigation into CVRx, Inc. regarding potential wrongdoings that may have affected investors. This follows a report from the Centers for Medicare and Medicaid Services proposing substantial cuts to reimbursement rates for CVRx's heart failure device. Specifically, rates are expected to decrease by 38.1% for Ambulatory Surgical Center services and 32.9% for hospital outpatient services, resulting in a significant drop in CVRx's stock value. The investigation invites investors to share information related to their purchases of CVRx securities.
Read more →CVRXCVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating CVRx, Inc. on potential claims related to securities law violations. The inquiry stems from concerns that CVRx may have issued misleading statements or failed to disclose critical information affecting investors. This comes after a significant decline in CVRx's stock price, attributed to proposed cuts in reimbursement rates for their heart failure device by the Centers for Medicare and Medicaid Services, which could impact future revenue.
Read more →CVRXCVRx Announces Increased Inpatient Payment for Barostim Procedure
CVRx, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure to a higher payment category, effective October 1, 2024. The new MS-DRG 276 assignment increases the average national payment from $17,000-$23,000 to approximately $43,000. This change aims to improve access to the Barostim therapy for patients with heart failure. CVRx's Barostim System is approved for use in heart failure patients and is a breakthrough medical technology that uses neuromodulation to address heart failure symptoms.
Read more →CVRX▲ +7.9%on this newsshared move
CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference
CVRx, Inc. has announced its participation in the Canaccord Genuity 44th Annual Growth Conference, scheduled for August 14, 2024. The company's management team will present via webcast, showcasing their technology aimed at treating heart failure. The Barostim™ System is noted for its FDA approval and CE Mark, marking significant milestones in its commercialization efforts.
Read more →CVRXCVRx Reports Second Quarter 2024 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported strong financial results for Q2 2024, achieving record revenue in its U.S. Heart Failure business. Revenue increased by 24% to $11.8 million, driven by growth in new sales territories and heightened therapist and patient awareness of its Barostim technology. However, the company faced a net loss of $14 million, an increase from the previous year's loss. Additionally, while U.S. sales flourished, revenues in Europe declined by 6%. Strengthening of the leadership team was also highlighted as a strategic move to enhance market development.
Read more →CVRXCVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024
CVRx, Inc. announced plans to report its second quarter 2024 financial and operating results on July 29th, 2024. The company will host a conference call to discuss these results at 4:30 PM Eastern time on the same day. CVRx specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being notable for its FDA approval and Breakthrough Device designation.
Read more →CVRXCVRx Announces Appointment of Robert Allen John as Chief Revenue Officer
CVRx has announced the appointment of Robert John as Chief Revenue Officer, effective June 27, 2024. John, who has over 25 years of experience in the medical device industry, will lead the company's US sales team to drive the adoption of Barostim therapy for heart failure patients. The CEO of CVRx, Kevin Hykes, expressed confidence in John's ability to enhance their commercial efforts. CVRx focuses on the development of the Barostim System, a unique neuromodulation device aimed at improving heart failure symptoms.
Read more →CVRXCVRx to Present at the William Blair 44th Annual Growth Stock Conference
CVRx, a commercial-stage medical device company, has announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 5, 2024. The presentation, scheduled for 8:40 AM Central Time, will be accessible through a live audio webcast. The company focuses on the Barostim System, an FDA-approved device designed to improve heart failure symptoms via neuromodulation.
Read more →CVRXCVRx Announces Key Senior Leadership Team Hires
CVRx announced key additions to its senior leadership team, including Dr. Philip B. Adamson as Chief Medical Officer, Bonnie Handke as Senior VP of Patient Access, and Jennifer E. Englund as Senior VP of Global Clinical Affairs. These appointments aim to enhance the adoption of the Barostim therapy for heart failure. Dr. Adamson brings extensive experience from Abbott Laboratories, while Handke and Englund have strong backgrounds in market access and clinical evidence generation respectively. The leadership changes are expected to drive awareness and validate the efficacy of Barostim.
Read more →CVRXCVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported its financial results for Q1 2024, with total revenue increasing to $10.8 million, a 35% rise from the previous year. Despite this growth, the company encountered challenges in its U.S. Heart Failure business linked to a recent management transition, leading to a management reshuffling. Additionally, CVRx reported a net loss of $22.2 million, a significant increase compared to the prior year. The company anticipates continued growth for its Barostim therapy, which is noted for improving patient outcomes in heart failure.
Read more →CVRXCVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
CVRx, Inc. announced plans to report its first quarter 2024 financial and operational results on April 30, 2024, followed by a conference call at 5:00 PM ET. The company specializes in the development and commercialization of Barostim™, an innovative device for treating cardiovascular diseases. This device is significant as it is the first FDA-approved neuromodulation technology designed for heart failure. A live webcast of the conference call will be available on the company’s investor relations website.
Read more →CVRXCVRx announces availability of additional data supporting long-term benefits of Barostim
CVRx, Inc. announced the publication of additional long-term data from the BeAT-HF trial in the European Journal of Heart Failure, revealing sustained benefits of the Barostim device for heart failure patients. The results indicate that Barostim, when combined with guideline-directed medical therapy, significantly improves patient quality of life and reduces the need for advanced heart failure interventions. Presentations at the THT conference further affirm its positive outcomes, showcasing promising data regarding reduced interventions and enhanced quality of life metrics. The company remains optimistic about further data generation through upcoming research initiatives.
Read more →CVRXCVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has serv
CVRx, Inc. has announced the appointment of Kevin Hykes as the new President and CEO, effective February 12, 2024. Hykes, who has extensive experience in the medical device industry, will take over from Nadim Yared, who is retiring. Hykes is currently serving as President and CEO of Augmedics and has held leadership roles in various successful companies. His deep understanding of CVRx is expected to facilitate a smooth transition as the company aims to expand the commercial adoption of its Barostim System for heart failure treatment.
Read more →CVRX▲ +5.7%on this news
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results MINNEAPOLIS
CVRx reported strong financial results for Q4 and the full year of 2023, showcasing a 97% increase in U.S. heart failure revenue. The company experienced significant milestones, including the expansion of its Barostim treatment labeling. Despite the success in the U.S. market, European revenue saw a decline, and the net loss remains a concern, although it improved compared to 2022. Looking ahead to 2024, CVRx is optimistic about its prospects and the importance of securing a high-caliber CEO for continued growth.
Read more →CVRXCVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
CVRx, Inc. plans to announce its fourth quarter 2023 financial and operational results on January 25th, 2024. Following the results, a conference call will be held at 4:30 PM ET, allowing investors to discuss the outcomes. The company focuses on developing Barostim™, a neuromodulation device for treating cardiovascular diseases and has received notable FDA approvals for its usage.
Read more →CVRX▼ -5.3%on this newsshared move
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% t
CVRx, Inc. has reported preliminary financial results for the fourth quarter and full year of 2023, expecting fourth quarter revenues of $11.2 million to $11.3 million, reflecting significant growth compared to the previous year. The company anticipates full-year revenues of approximately $39.2 million to $39.3 million, marking a notable increase from 2022. Additionally, CEO Nadim Yared has announced his upcoming retirement, with a search process for his successor underway. The company aims to maintain strong leadership and further growth in 2024, leveraging recent positive developments in its Barostim therapy.
Read more →CVRXCVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CVRx, a commercial-stage medical device company, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will take place at 3:45 PM Pacific Time and will be available via live audio webcast. CVRx specializes in neuromodulation solutions for cardiovascular conditions, notably their FDA-approved Barostim device, which aids heart failure patients.
Read more →CVRX▲ +24.2%on this newsshared move
CVRx receives FDA approval for expanded labeling of Barostim U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data MINNEAPOLIS
CVRx, Inc. has received FDA approval for revised labeling of its Barostim device, incorporating significant long-term data from the BeAT-HF clinical trial. This approval is anticipated to enhance the market opportunity for Barostim, with estimates rising to $2.2 billion based on real-world adoption and updated safety and efficacy data. The device aims to improve heart failure symptoms by activating baroreflexes through electrical pulses delivered to the carotid artery. Despite the positive developments, the primary endpoint related to CV death and HF hospitalization in the Post-Market Phase was not achieved.
Read more →CVRXCVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
CVRx, Inc. will present at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023. The presentation will highlight the company's progress in developing neuromodulation solutions for cardiovascular diseases, particularly their FDA-approved device, Barostim. The Barostim device has received Breakthrough Device designation and is designed to alleviate heart failure symptoms by balancing the autonomic nervous system. A live webcast of the presentation will be available on the company's investor relations page.
Read more →CVRXCVRx Reports Third Quarter 2023 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported its third-quarter financial results for 2023, showcasing dynamic growth in revenue, particularly from its heart failure business in the U.S., which saw a 90% increase. The company achieved a total revenue of $10.5 million, significantly up from the previous year due to expanded sales efforts and increased awareness. However, it continues to face a net loss of $9 million and a decline in revenue from the European market. Looking ahead, CVRx anticipates managing reduced quarterly cash burn as it strives for sustained growth into 2024.
Read more →CVRXCVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
CVRx, a medical device company, will announce its third quarter 2023 financial and operating results on October 26th, 2023. Following the release, a conference call will be held to discuss these results. CVRx is known for its Barostim device, which has received FDA approval for treating heart failure, showcasing its commitment to addressing cardiovascular diseases. Investors can participate in the conference call via telephone or through a live webcast on the company's website.
Read more →CVRXCVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
CVRx, Inc., a medical device company specializing in neuromodulation for cardiovascular disorders, announced its participation in the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The presentation will showcase its innovative product, Barostim, which aims to alleviate symptoms in heart failure patients. Barostim has received FDA approval and Breakthrough Device designation, indicating its potential impact on treatment options in this area. Interested parties can access a live audio webcast of the presentation on CVRx's investor relations webpage.
Read more →CVRXCVRx Reports Second Quarter 2023 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported strong financial results for the second quarter of 2023, with revenue reaching $9.5 million, marking a nearly 89% increase over the prior year. The U.S. heart failure business saw particularly impressive growth, contributing to a total revenue increase driven by expanded sales territories and heightened awareness of the Barostim device. Despite these positive developments, the company also noted a slight increase in net loss and elevated operational expenses, raising concerns about financial sustainability amid reliance on a single product. Looking ahead, CVRx projects continued revenue growth for the third quarter of 2023, indicating an optimistic outlook for the remainder of the year.
Read more →CVRXCVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
CVRx, Inc. announced that it will release its second quarter 2023 financial and operating results on July 25th, 2023, after market close. A conference call is scheduled for the same day at 5:30 p.m. Eastern Time to discuss the results. The company focuses on developing the Barostim device, designed to help patients with heart failure by restoring balance to the autonomic nervous system. Barostim is recognized as a breakthrough in medical technology with FDA and CE Mark approvals.
Read more →CVRXCVRx Set to Join Russell 2000 & 3000 Indexes
CVRx, Inc. announced its inclusion in the Russell 2000 and 3000 Indexes, effective June 26, 2023. This addition signifies the company's established market position and commitment to value for shareholders. The Russell Indexes are crucial for investors as they benchmark significant assets, making CVRx's membership notable. CEO Nadim Yared expressed optimism about the opportunities this recognition brings while continuing to focus on improving patient lives with their innovative neuromodulation solutions, particularly the FDA-approved Barostim device.
Read more →CVRX▲ +16%on this news
rd Annual William Blair Growth Stock Conference, June 2023 2 Cautionary Note Regarding Forward-Looking Statement This presentation by CVRx, Inc. (the “Company”) contains forward-looking statements within th
CVRx, Inc. recently shared optimistic results on the financial and clinical performance of Barostim, a device for heart failure treatment. The company reported a remarkable 132% increase in U.S. heart failure revenue, totaling $6.8 million for Q1 2023. Projections for the full year suggest total revenue could reach between $35.5 million and $38.0 million. Additionally, clinical results indicate Barostim safely and effectively improves heart failure symptoms, with an ongoing focus on further labeling expansions with the FDA.
Read more →CVRXCVRx to Present at the William Blair 43rd Annual Growth Stock Conference
CVRx, Inc. announced its participation in the William Blair 43rd Annual Growth Stock Conference scheduled for June 8, 2023. The company's management team will present at 9:20 am Central Time, highlighting their innovative neuromodulation solutions for cardiovascular diseases. Their product, Barostim, is the first FDA-approved device in this category, indicating a strong position within the industry.
Read more →CVRXCVRx Reports First Quarter 2023 Financial and Operating Results MINNEAPOLIS
CVRx, Inc. reported positive financial results for Q1 2023, with a notable revenue growth of 96% year-over-year, reaching $8.0 million. The company expanded its U.S. heart failure business with an increase in active implanting centers and sales territories. Despite these gains, CVRx experienced a net loss of $11.4 million, and expenses in R&D saw a significant rise. Overall, the results reflect strong execution but underline ongoing financial challenges faced by the company.
Read more →CVRXCVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023
CVRx, Inc. has announced that it will release its financial and operating results for the first quarter of 2023 on April 27th. The company will host a conference call to discuss these results, which will occur after market close. CVRx focuses on the development of Barostim™, an implantable device aimed at treating patients with cardiovascular diseases and has received FDA approval and CE Mark certifications.
Read more →CVRXTotality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure MINNEAPOLIS
CVRx, a commercial-stage medical device company, announced preliminary results of the BeAT-HF trial, highlighting the long-term benefits of its Barostim device for patients with heart failure. Dr. Michael Zile presented the data at the THT conference, concluding that Barostim is a safe and effective treatment option. CVRx plans to submit this new data to the FDA to pursue expanded labeling for Barostim in the coming months. The positive findings indicate increased interest and adoption of the therapy, contributing to CVRx's growth strategy.
Read more →CVRX▲ +8.7%on this newsshared move
CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
CVRx, Inc. is set to present preliminary results from the post-market phase of the BeAT-HF trial at the upcoming THT 2023 conference on March 21, 2023. The results will be shared by Dr. Michael Zile, a Professor of Cardiology, during a dedicated symposium. In addition, CVRx will conduct an investor conference call on the same day to further discuss the results, signifying transparency and engagement with stakeholders. The company's Barostim™ device continues to show promise in treating cardiovascular diseases through neuromodulation.
Read more →CVRX▼ -58.8%on this news
CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial The trial did not meet its primary endpoint, however, the totality of data supports Barostim's use as an effective treatment for patie
CVRx, Inc. announced preliminary results from the BeAT-HF clinical trial, which investigated Barostim for heart failure treatment. Although the trial did not achieve its primary endpoint, additional analyses indicated potential benefits of Barostim, such as improvement in survival and quality of life for patients. The company plans to share these findings at an upcoming conference and is seeking FDA approval for expanded indications. The ongoing safety and efficacy of Barostim are emphasized, given positive historical data supporting its clinical utility.
Read more →CVRXCVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year MINNEAPOLIS
CVRx, Inc. reported a strong financial performance for the fourth quarter and full year of 2022, featuring a remarkable 96% increase in revenue to $7.2 million compared to the same period last year. The company's growth in the heart failure business was particularly notable, with the U.S. segment seeing a more than doubling in revenue. Factors contributing to this success include the expansion into new territories, increased physician and patient awareness of their Barostim device, and a rise in active implanting centers. For 2023, CVRx remains optimistic about continuing this upward trend.
Read more →CVRXCVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will announce its fourth quarter and fiscal year 2022 financial results on January 26, 2023. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time on the same day. CVRx's Barostim device, which recently received FDA approval, aims to improve symptoms in heart failure patients, reflecting the company's innovative approach in the medical device sector.
Read more →CVRXCVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results MINNEAPOLIS
CVRx, Inc. has announced preliminary financial results for the fourth quarter and full year of 2022, reporting approximately $7.0 million to $7.1 million in Q4 revenue, a substantial increase from the previous year. Total revenues for 2022 are expected to be between $22.3 million and $22.4 million, reflecting a 71% to 72% increase over 2021. The company has also grown the number of active implanting centers and is optimistic about achieving greater penetration of its Barostim technology in 2023. A detailed financial report is expected later in January.
Read more →CVRXCVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the managem
Read more →CVRXCVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today
Read more →CVRXCVRx to Present at the Piper Sandler 34th Annual Healthcare Conference
MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the managem
Read more →CVRX▲ +16.3%on this news
CVRx Launches new Barostim NEO2™ Implantable Pulse Generator
The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of th
Read more →CVRX▲ +16.3%on this news
CVRx to Attend Upcoming Investor Conferences
MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the manageme
Read more →CVRXCVRx Reports Third Quarter 2022 Financial and Operating Results Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year MINNEAPOLIS
CVRx Reports Third Quarter 2022 Financial and Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year MINNEAPOLIS, November 1, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and
Read more →CVRXCVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022
MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to
Read more →CVRX▲ +17%on this news
CVRx to Present at the Canaccord Genuity 42nd Annual Growth Conference
MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the manageme
Read more →CVRXCVRx Reports Second Quarter 2022 Financial and Operating Results Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year MINNEAPOLIS
CVRx Reports Second Quarter 2022 Financial and Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and co
Read more →CVRX▲ +5.3%on this news
CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to
Read more →CVRXCVRx Launches a new Barostim™ Programmer
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Adm
Read more →CVRXCVRx to Present at the William Blair 42nd Annual Growth Stock Conference
MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the managemen
Read more →CVRXCVRx Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has
Read more →CVRXCVRx Reports First Quarter 2022 Financial and Operating Results First Quarter 2022 Revenue of $4.1 million, a 43% Increase Over Prior Year MINNEAPOLIS
CVRx Reports First Quarter 2022 Financial and First Quarter 2022 Revenue of $4.1 million, a 43% Increase Over Prior Year MINNEAPOLIS, April 25, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufa
Read more →CVRXCVRx to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to
Read more →CVRX▲ +7.6%on this news
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS, February 15, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company
Read more →CVRXCVRx to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 15, 2022
MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to
Read more →CVRX▼ -12%on this news
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results MINNEAPOLIS
Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results MINNEAPOLIS, January 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutio
Read more →CVRXCVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the manageme
Read more →CVRX▼ -12.1%on this news· ran to -28% by day 3
CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today anno
Read more →CVRXCVRx Reports Third Quarter 2021 Financial and Operating Results Third Quarter 2021 Revenue of $3.4 million, a 241% Increase Over Prior Year MINNEAPOLIS
CVRx Reports Third Quarter 2021 Financial and Third Quarter 2021 Revenue of $3.4 million, a 241% Increase Over Prior Year MINNEAPOLIS, November 4, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, man
Read more →CVRXCVRx to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call
MINNEAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today anno
Read more →CVRXCVRx Added to Russell 2000 and 3000 Indexes
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular dise
Read more →CVRXCVRx Reports Second Quarter 2021 Financial and Operating Results Second Quarter 2021 Revenue of $3.1 million, a 150% Increase Over Prior Year MINNEAPOLIS
CVRx Reports Second Quarter 2021 Financial and Second Quarter 2021 Revenue of $3.1 million, a 150% Increase Over Prior Year MINNEAPOLIS, August 4, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, man
Read more →CVRXCVRx to Present at the Canaccord Genuity 41st Annual Growth Conference
MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today anno
Read more →CVRXCVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today ann
Read more →CVRX▲ +8.4%on this news
CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors
MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announces
Read more →CVRXCVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced
Read more →CVRXCVRx, Inc. Announces Upsized Pricing of Initial Public Offering
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced
Read more →CVRXCVRx Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the first clinical procedure with the company’s new lead implantation approach. The no
Read more →CVRXCVRx Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding its senior leadership team by adding two medical device veterans to the sales and m
Read more →CVRXCVRx BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for Medicare and Medicaid Services (CMS) granted approval for a transitional pass-throu
Read more →CVRXCVRx Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice Pre
Read more →Competitive Position
How CVRX ranks across every disease it competes inCompetitive Position is a premium feature
See how CVRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial